Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SYNCAR-001 |
Synonyms | |
Therapy Description |
SYNCAR-001 are T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD19 as well as a mutated IL-2 receptor beta, which have potential antitumor activity (Cancer Res (2021) 81 (13_Supplement): 1512). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SYNCAR-001 | SYNCAR 001|SYNCAR001 | CD19 Immune Cell Therapy 62 | SYNCAR-001 are T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD19 as well as a mutated IL-2 receptor beta, which have potential antitumor activity (Cancer Res (2021) 81 (13_Supplement): 1512). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|